entertainment -WSS

entertainment

author：explore 2025-10-02 13:41:00 - browse：2444

Adam's take main illustration — Molly Ferguson/STAT

The eye disease physician in charge of a committee that flagged a rare but severe side effect involving a newly approved drug from Apellis Pharmaceuticals has financial ties to a competing drugmaker. The conflict raises questions about his supervision of an emerging safety issue for patients and its impact on the financial health of Apellis.

Peter Kaiser, a retinal disease expert who runs the Cole Eye Institute at the Cleveland Clinic, failed to report consulting fees and stock ownership in Iveric Bio on a financial disclosure form maintained by the American Society of Retina Specialists, or ASRS. Iveric Bio is developing a treatment for geographic atrophy, a common, age-related cause of vision loss and the same indication for which the Apellis drug was approved.

The financial conflict, which was undisclosed until after Kaiser was contacted about it by STAT, is relevant because Kaiser also chairs a committee of the ASRS responsible for monitoring the safety of retina drugs and devices. On July 15, Kaiser’s committee sent a letter to member doctors, alerting them to reports of eye inflammation in people receiving injections of Syfovre, the treatment recently approved and launched by Apellis.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How one medical school became remarkably diverse
Next article： This gene therapy has record $4.25 million price. It's saved children.

WSS

Pregnancy ages women, but effects reverse after delivery

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

Chinese researcher claims birth of first gene

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

With Wegovy coverage, Medicare patients may face high costs

Cancer, immunology, HIV research ensnared in fetal tissue politics

hotspot

entertainment

hotspot

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Testing GLP

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Ascension's ugly legal battle over care for poor patients in Texas

Cancer drug shortages should be causing more outrage

Merck to acquire Harpoon Therapeutics for $680 million

Novavax promises a turnaround & Lilly roils the obesity market

Surgeons perform first xenotransplant using CRISPR'd pig kidney

Psychedelics group wrestles with new pharma identity

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

explore

Does Paxlovid work in people vaccinated against Covid

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

'Patient friction coefficient' can gauge a clinical trial's patient burden

Medicare Advantage insurers pressure Biden for bigger payments

Chinese researcher claims birth of first gene

Yancopoulos of Regeneron works to expand Dupixent success

focus

Wikipedia

Wikipedia

focus